AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00589654 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.
Study NCT04511702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegloticase with MTX
Description: Participants will receive MTX during the run-in period then pegloticase with MTX for up to 24 weeks during the treatment period
Study NCT00983515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.
Study NCT00983515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19
Study NCT00983515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
Study NCT04663347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone
Description: 21-day cycles
Study NCT04663347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab and lenalidomide
Description: 28-day cycles
Study NCT04663347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab and bendamustine
Description: 28-day cycles
Study NCT04663347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin
Description: 21-day cycles
Study NCT04663347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and oxaliplatin
Description: 28-day cycles
Study NCT04663347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.
Study NCT04663347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone
Description: 21-day cycles
Study NCT04663347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 28-day cycles
Study NCT04663347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab, ifosfamide, carboplatin, and etoposide phosphate
Description: 21-day cycles
Study NCT04663347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.
Study NCT04663347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until disease progression or unacceptable toxicity.
Study NCT04663347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.
Study NCT04663347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1 and then every 8 weeks for a total of 2 years.
Study NCT04663347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.
Study NCT04663347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.
Study NCT04663347 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until transplant or disease progression.
Study NCT01757626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu3F8 With GM-CSF
Description: Ph I: 1 cycle consists of treatment with hu3F8 for 3 days (day 1, 3 \& 5). GM-CSF starts 5 days in advance of each hu3F8 cycle at 250 mcg/m\^2/day (day -4 to day 0), \& at 500 mcg/m\^2/day x 5 days (day 1 to day 5). Hu3F8 cycles are 5 days. Ph II pts may receive treatment on a modified schedule of 3 doses of IV hu3F8 over a maximum of 10 days, as needed. With modified schedules of hu3F8, GM-CSF will be administered at 250 mcg/m2/day x5 days before the 1st dose of hu3F8, as with the standard schedule, but then GM-CSF at 500 mcg/m2/day will be administered on day of the 1st dose of hu3F8, on the day before and on the day of the 2nd dose of hu3F8, and on the day before and on the day of the 3rd dose of hu3F8. Cycles are repeated at 2-4 week intervals between 1st days of hu3F8, through 4 cycles. Pts who complete 4 cycles of treatment w/o complications or disease progression have the option of continuing treatment for up to 24 months from their 1st dose of hu3F8.
Study NCT01757626 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hu3F8 With GM-CSF
Description: As determined by the phase I component of the study, the hu3F8 dosage in the phase II portion is 3 mg/kg/day. Patients who were treated in the phase I component are eligible for treatment in the phase II portion. Cycles are repeated approximately monthly through 5 cycles. Group 1 and Group 3 patients can continue to receive cycles every 1-2 months for up to 24 months from study enrollment or until they receive 5 cycles after a major response (CR or PR) is achieved, whichever comes first. If HAHA becomes (+), cycles are deferred until it becomes (-) again. Patients who develop HAHA which precludes timely treatments with hu3F8+GM-CSF are eligible to receive low-dose maintenance regimens such as irinotecan alone,61 temozolomide alone,62 irinotecan-temozolomide,63 or cyclophosphamide-topotecan.64 They can also receive anti-HAHA agents such as rituximab and cyclophosphamide. They resume treatment with hu3F8+ GM-CSF if HAHA becomes negative. Patients may receive local radiation therapy.
Study NCT03029299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FilmArray RP EZ
Description: Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
Study NCT02500147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
Study NCT03362216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound Methyl Salicylate Liniment
Description: Compound Methyl Salicylate Liniment, apply to the affected area, 3 times a day.Course of treatment: 7 days
Study NCT03362216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Sodium Liniment
Description: Diclofenac Sodium Liniment, apply to the affected area, 3 times a day. Course of treatment: 7 days
Study NCT03170089 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Health Educational Program
Description: Oral Hygiene methods learned
Study NCT02975206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serlopitant High Dose
Description: serlopitant tablets - high dose
Study NCT02975206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo tablet
Study NCT02975206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serlopitant Low Dose
Description: serlopitant tablets - low dose
Study NCT00508820 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
Study NCT02263924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienol
Description: Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months
Study NCT02263924 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
Study NCT00755521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoricoxib
Description: Treating Fibromyalgia with etoricoxib~etoricoxib - 90mg
Study NCT00144456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ED-71
Description: 0.75μg/day(p.o.)for 144 weeks
Study NCT00144456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol
Description: 1.0μg/day(p.o.)for 144 weeks
Study NCT03643640 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimune
Description: Optimune is a web-based psychological intervention developed for women with breast cancer.
Study NCT03643640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care-As-Usual
Description: Participants are free to continue to engage with any treatment they require (i.e., CAU).
Study NCT02500147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
Study NCT00144456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ED-71 placebo
Description: 0 μg/day(p.o.)for 144 weeks
Study NCT00144456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfacalcidol placebo
Description: 0 μg/day(p.o.)for 144 weeks
Study NCT03602521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interpersonal stress
Description: Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~* 1) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~* 2) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?
Study NCT03602521 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interpersonal stress
Description: Through an interview the evaluator will make a 1 to 2 pages script, written in first-person and in present tense. It will involve an interpersonal conflict between the participants and the person who once trigger their feeling of abandonment.~After reading the script the participants will have to close their eyes and imagine the event as if was happening to them, now, in real time, and think about it during 3 minutes.~To evaluate the stress efficiency, the evaluator will ask 2 questions :~* 1) from 0 (no distress at all) to 10 (maximal unimaginable distress), to wich point this script bring distress to you?~* 2) from 0 (I can not at all) to 10 (I can completely), to wich point are you able to imagine the scenario in real time, as if you were living it?
Study NCT02132169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: AC-170 0.24%
Study NCT02132169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AC-170 0%
Study NCT03702023 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: Intervention group will receive 1000 mg of acetaminophen
Study NCT03702023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Control group will be given a placebo capsule.
Study NCT00888316 — intervention group
Intervention type: PROCEDURE
Intervention: magnetic resonance imaging
Description: MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.~The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC.
Study NCT00888316 — intervention group
Intervention type: PROCEDURE
Intervention: Serum ferritin
Description: Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
Study NCT00878644 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Hypothermia
Description: Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
Study NCT00878644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Normothermia
Description: Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
Study NCT03224936 — intervention group
Intervention type: DEVICE
Intervention: PSI
Description: The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
Study NCT03109418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
Study NCT03109418 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: OSA patients receiving standard inhaled anesthesia combined with normal saline
Study NCT01432756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Let's Talk Worksite Parenting Program
Description: The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
Study NCT00722410 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: VSL#3
Description: A probiotic preparation.
Study NCT00722410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Description: Oral ingestion of 3 liters of polyethylene glycol solution.
Study NCT04623268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound and questionnaire
Description: One invititation to identified adult offspring to have an ultrasound to detect an AAA. The prevalence in this Group (strata for sex) will be compared to a random selected matched Control group
Study NCT02068846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Over encapsulated Ciprofloxacin 500 mg will be taken twice daily for 28 days.
Study NCT02068846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will over encapsulated to match active treatment, taken twice daily for 28 days.
Study NCT04594265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KetoneAid KE4 Pro Monoester
Description: A dietary supplement containing ketone monoester.
Study NCT04594265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: KetoneAid KE4 Pro Monoester
Description: A dietary supplement containing ketone monoester.
Study NCT04594265 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Science in Sport Go Enegy
Description: Dosis isocaloric to the KetoneAid Arm
Study NCT03258281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evolocumab
Description: Patients will receive evolocumab 420 mg administered subcutaneously
Study NCT03258281 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo administered subcutaneously
Study NCT02947854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimaporfin (Photosensitizer)
Study NCT02947854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiltonol (Poly-ICLC)
Study NCT02947854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV E7 (Human Papilloma Virus E7) peptides
Study NCT02947854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH (Keyhole Limpet Hemocyanin)
Study NCT00803257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbrical splint and Lumbrical exercises
Description: Subjects receive one of four possible interventions - Dose and Frequency are the same for each
Study NCT00803257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lumbrical splint and Lumbrical exercises
Description: Subjects receive one of four possible interventions - Dose and Frequency are the same for each
Study NCT00182780 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: American ginseng
Study NCT00182780 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study NCT00962169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral and managerial
Description: The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
Study NCT00962169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral and IT
Description: The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
Study NCT02526524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets
Study NCT02526524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Met IR
Description: metformin immediate-release tablets
Study NCT02526524 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02562209 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PACER Diet
Description: Pacer diet to be followed for 8 weeks
Study NCT02562209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard weight reducing diet
Description: Standard weight reducing diet to be followed for 8 weeks
Study NCT01971463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: intravenous administration of 500cc of 0.9% NaCl over 30 minutes
Study NCT03396679 — intervention group
Intervention type: OTHER
Intervention: Ultrasound examination
Description: Evaluation of the Psoriatic Arthritis remission according to patient and physician's global assessment of disease activity are in agreement (CASPAR criteria agreement) or in disagreement (CASPAR criteria disagreement)
Study NCT04385238 — intervention group
Intervention type: OTHER
Intervention: This is an online survey with no intervention.
Description: As this is an online survey about health and wellbeing, there is no intervention.
Study NCT04465435 — intervention group
Intervention type: OTHER
Intervention: Web-based self-report questionnaires
Description: Web-based self-report questionnaires based on well established instruments.
Study NCT04465435 — intervention group
Intervention type: OTHER
Intervention: Focus Group Interviews
Description: Group conversation with open-ended questions with 7-10 students/group on topics relevant to the aim of the study.
Study NCT02676336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Violet™ Molecular Iodine (I2)
Study NCT02676336 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00989521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PUR003
Description: PUR003 for inhalation
Study NCT00989521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline for inhalation
Study NCT04607941 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Self-administered questionnaires
Study NCT00655499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg